{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:35:46Z","timestamp":1772120146270,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13577-020-00413-y","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T13:05:57Z","timestamp":1598706357000},"page":"1112-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["INNO-406 inhibits the growth of chronic myeloid leukemia and promotes its apoptosis via targeting PTEN"],"prefix":"10.1007","volume":"33","author":[{"given":"Jiandong","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-5057","authenticated-orcid":false,"given":"Lirong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"413_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia\u2013advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451\u201364.","journal-title":"N Engl J Med"},{"key":"413_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"413_CR3","first-page":"1441","volume":"61","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer-Am Cancer Soc. 1988;61:1441\u20136.","journal-title":"Cancer-Am Cancer Soc"},{"key":"413_CR4","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640\u201353.","journal-title":"Blood"},{"key":"413_CR5","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"413_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441\u201353.","journal-title":"Nat Rev Cancer"},{"key":"413_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.1365-2141.2000.02137.x","volume":"110","author":"CG Geary","year":"2000","unstructured":"Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110:2\u201311.","journal-title":"Br J Haematol"},{"key":"413_CR8","first-page":"1450","volume":"11","author":"FP Santos","year":"2010","unstructured":"Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl\/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs. 2010;11:1450\u201365.","journal-title":"Curr Opin Investig Drugs"},{"key":"413_CR9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ejca.2013.01.001","volume":"49","author":"J Portnow","year":"2013","unstructured":"Portnow J, Badie B, Markel S, et al. A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl\/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. Eur J Cancer. 2013;49:1634\u201340.","journal-title":"Eur J Cancer"},{"key":"413_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4137\/117739010700200008","volume":"2","author":"T Niwa","year":"2007","unstructured":"Niwa T, Asaki T, Kimura S. NS-187 (INNO-406), a Bcr-Abl\/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights. 2007;2:93\u2013106.","journal-title":"Anal Chem Insights"},{"key":"413_CR11","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005;106:3948\u201354.","journal-title":"Blood"},{"key":"413_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","volume":"32","author":"Y Deguchi","year":"2008","unstructured":"Deguchi Y, Kimura S, Ashihara E, et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res. 2008;32:980\u20133.","journal-title":"Leuk Res"},{"key":"413_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","volume":"109","author":"A Yokota","year":"2007","unstructured":"Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCR-ABL\/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007;109:306\u201314.","journal-title":"Blood"},{"key":"413_CR14","doi-asserted-by":"publisher","first-page":"25694","DOI":"10.1038\/srep25694","volume":"6","author":"YK Zhang","year":"2016","unstructured":"Zhang YK, Zhang GN, Wang YJ, et al. Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Sci Rep. 2016;6:25694.","journal-title":"Sci Rep"},{"key":"413_CR15","first-page":"2665","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, le Coutre P, Cortes J, et al. Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer-Am Cancer Soc. 2010;116:2665\u2013722.","journal-title":"Cancer-Am Cancer Soc"},{"key":"413_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/FJC.0000000000000732","volume":"74","author":"X Yang","year":"2019","unstructured":"Yang X, Chen G, Chen Z. MicroRNA-200a-3p Is a positive regulator in cardiac hypertrophy through directly targeting WDR1 as well as modulating PTEN\/PI3K\/AKT\/CREB\/WDR1 signaling. J Cardiovasc Pharmacol. 2019;74:453\u201361.","journal-title":"J Cardiovasc Pharmacol"},{"key":"413_CR17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41419-018-0689-4","volume":"9","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ouyang Q, Fu R, et al. The cyclohexene derivative MC-3129 exhibits antileukemic activity via RhoA\/ROCK1\/PTEN\/PI3K\/Akt pathway-mediated mitochondrial translocation of cofilin. Cell Death Dis. 2018;9:656.","journal-title":"Cell Death Dis"},{"key":"413_CR18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1111\/jth.13755","volume":"15","author":"Z Cheng","year":"2017","unstructured":"Cheng Z, Gao W, Fan X, et al. Extracellular signal-regulated kinase 5 associates with casein kinase II to regulate GPIb-IX-mediated platelet activation via the PTEN\/PI3K\/Akt pathway. J Thromb Haemost. 2017;15:1679\u201388.","journal-title":"J Thromb Haemost"},{"key":"413_CR19","doi-asserted-by":"publisher","first-page":"1389653","DOI":"10.1155\/2019\/1389653","volume":"2019","author":"X Luo","year":"2019","unstructured":"Luo X, Zhou N, Wang L, Zeng Q, Tang H. Long noncoding RNA GATA3-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by suppression of PTEN, CDKN1A, and TP53. Can J Gastroenterol Hepatol. 2019;2019:1389653.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"413_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2015.00024","volume":"5","author":"M Milella","year":"2015","unstructured":"Milella M, Falcone I, Conciatori F, et al. PTEN: multiple functions in human malignant tumors. Front Oncol. 2015;5:24.","journal-title":"Front Oncol"},{"key":"413_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tibs.2014.02.006","volume":"39","author":"BD Hopkins","year":"2014","unstructured":"Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. PTEN function: the long and the short of it. Trends Biochem Sci. 2014;39:183\u201390.","journal-title":"Trends Biochem Sci"},{"key":"413_CR22","first-page":"3667","volume":"23","author":"A Li","year":"2017","unstructured":"Li A, Qiu M, Zhou H, Wang T, Guo W. PTEN, insulin resistance and cancer. Curr Pharm Des. 2017;23:3667\u2013766.","journal-title":"Curr Pharm Des"},{"key":"413_CR23","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1038\/onc.2015.515","volume":"35","author":"J Musa","year":"2016","unstructured":"Musa J, Orth MF, Dallmayer M, et al. Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis. Oncogene. 2016;35:4675\u201388.","journal-title":"Oncogene"},{"key":"413_CR24","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1158\/0008-5472.CAN-09-1923","volume":"69","author":"YY Kim","year":"2009","unstructured":"Kim YY, Von Weymarn L, Larsson O, et al. Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res. 2009;69:8455\u201362.","journal-title":"Cancer Res"},{"key":"413_CR25","first-page":"792","volume":"19","author":"CY Cheng","year":"2019","unstructured":"Cheng CY, Kao ST, Lee YC. Ferulic acid ameliorates cerebral infarction by activating Akt\/mTOR\/4EBP1\/Bcl2 antiapoptotic signaling in the penumbral cortex following permanent cerebral ischemia in rats. Mol Med Rep. 2019;19:792\u2013804.","journal-title":"Mol Med Rep"},{"key":"413_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.tranon.2018.11.001","volume":"12","author":"A Nogami","year":"2019","unstructured":"Nogami A, Okada K, Ishida S, Akiyama H, Umezawa Y, Miura O. Inhibition of the STAT5\/Pim kinase axis enhances cytotoxic effects of proteasome inhibitors on FLT3-ITD-positive AML cells by cooperatively inhibiting the mTORC1\/4EBP1\/S6K\/Mcl-1 pathway. Transl Oncol. 2019;12:336\u201349.","journal-title":"Transl Oncol"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00413-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-020-00413-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00413-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T20:04:41Z","timestamp":1630181081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-020-00413-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1007\/s13577-020-00413-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-16330\/v1","asserted-by":"object"}]},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,29]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflicts of interest exist in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}